Literature DB >> 6314275

The adenovirus-2 EIIa early gene promoter: sequences required for efficient in vitro and in vivo transcription.

R Elkaim, C Goding, C Kédinger.   

Abstract

A series of deletion mutants extending from -250 toward the capsite has been constructed in the early promoter region of the adenovirus 2 EIIa gene and tested both in vitro, and in vivo after transfection of HeLa cells, for the ability to act as a template for transcription. A region between positions -94 and -63 upstream from the major EIIa early cap site is essential both in vivo and in vitro for efficient promoter function. By cotransfection of the EIIa deletion mutants with the EIa transcription unit it has been possible to demonstrate that deletion to position -94 does not affect induction of transcription of the EIIa early gene by the EIa transcription unit, but deletion to position -63 results in loss of detectable levels of EIIa early specific RNA. Thus, sequences upstream from position -94 of the EIIa early gene are not involved in the induction of the EIIa early gene by the EIa transcription unit.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6314275      PMCID: PMC326441          DOI: 10.1093/nar/11.20.7105

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  33 in total

1.  Construction and characterization of amplifiable multicopy DNA cloning vehicles derived from the P15A cryptic miniplasmid.

Authors:  A C Chang; S N Cohen
Journal:  J Bacteriol       Date:  1978-06       Impact factor: 3.490

2.  Loop structures in hybrids of early RNA and the separated strands of adenovirus DNA.

Authors:  G R Kitchingman; S P Lai; H Westphal
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

3.  Complex splicing patterns of RNAs from the early regions of adenovirus-2.

Authors:  L T Chow; T R Broker; J B Lewis
Journal:  J Mol Biol       Date:  1979-10-25       Impact factor: 5.469

4.  Thermolabile DNA binding proteins from cells infected with a temperature-sensitive mutant of adenovrius defective in viral DNA synthesis.

Authors:  P C Van Der Vliet; A J Levine; M J Ensinger; H S Ginsberg
Journal:  J Virol       Date:  1975-02       Impact factor: 5.103

5.  Sequencing end-labeled DNA with base-specific chemical cleavages.

Authors:  A M Maxam; W Gilbert
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

6.  Ovalbumin gene: evidence for a leader sequence in mRNA and DNA sequences at the exon-intron boundaries.

Authors:  R Breathnach; C Benoist; K O'Hare; F Gannon; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

7.  Messenger RNA for the Ad2 DNA binding protein: DNA sequences encoding the first leader and heterogenity at the mRNA 5' end.

Authors:  C C Baker; J Herisse; G Courtois; F Galibert; E Ziff
Journal:  Cell       Date:  1979-10       Impact factor: 41.582

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

9.  Structure of the adenovirus 2 early mRNAs.

Authors:  A J Berk; P A Sharp
Journal:  Cell       Date:  1978-07       Impact factor: 41.582

10.  The E1b promoter of Ad12 in mouse L tk- cells is activated by adenovirus region E1a.

Authors:  J L Bos; H C ten Wolde-Kraamwinkel
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  37 in total

1.  Phosphorylation-dependent activation of the adenovirus-inducible E2F transcription factor in a cell-free system.

Authors:  S Bagchi; P Raychaudhuri; J R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

2.  The C-terminal 70 amino acids of the adenovirus E4-ORF6/7 protein are essential and sufficient for E2F complex formation.

Authors:  R J O'Connor; P Hearing
Journal:  Nucleic Acids Res       Date:  1991-12-11       Impact factor: 16.971

3.  Promiscuous trans activation of gene expression by an Epstein-Barr virus-encoded early nuclear protein.

Authors:  P M Lieberman; P O'Hare; G S Hayward; S D Hayward
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

4.  Identical genomic footprints of the adenovirus EIIa promoter are detected before and after EIa induction.

Authors:  B Devaux; G Albrecht; C Kedinger
Journal:  Mol Cell Biol       Date:  1987-12       Impact factor: 4.272

5.  A specific domain of the adenovirus EIV promoter is necessary to maintain susceptibility of the integrated promoter to EIA transactivation.

Authors:  T Nishigaki; S Hanaka; R E Kingston; H Handa
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

6.  The abundance and in vitro DNA binding of three cellular proteins interacting with the adenovirus EIIa early promoter are not modified by the EIa gene products.

Authors:  P Jalinot; B Devaux; C Kédinger
Journal:  Mol Cell Biol       Date:  1987-10       Impact factor: 4.272

7.  The E4 promoter of adenovirus type 2 contains an E1A dependent cis-acting element.

Authors:  P Gilardi; M Perricaudet
Journal:  Nucleic Acids Res       Date:  1986-11-25       Impact factor: 16.971

8.  Identification of a factor in HeLa cells specific for an upstream transcriptional control sequence of an EIA-inducible adenovirus promoter and its relative abundance in infected and uninfected cells.

Authors:  L SivaRaman; S Subramanian; B Thimmappaya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

9.  Adenovirus EIIA early promoter: transcriptional control elements and induction by the viral pre-early EIA gene, which appears to be sequence independent.

Authors:  S C Murthy; G P Bhat; B Thimmappaya
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

10.  An enhancer-like element in the adenovirus E2 promoter contains sequences essential for uninduced and E1A-induced transcription.

Authors:  M J Imperiale; R P Hart; J R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.